Everything below concerns Albumin conjugation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-06. Numbers and descriptions here follow the published literature rather than marketing material.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Due to its importance to life, blood is associated with a large number of beliefs. One of the most basic is the use of blood as a symbol for family relationships through birth/parentage; to be "related by blood" is to be related by ancestry or descendence, rather than marriage. This bears closely to bloodlines, and sayings such as "blood is thicker than water" and "bad blood", as well as "Blood brother". Blood is given particular emphasis in the Islamic, Jewish, and Christian religions, because Leviticus 17:11 says "the life of a creature is in the blood." This phrase is part of the Levitical law forbidding the drinking of blood or eating meat with the blood still intact instead of being poured off. Mythic references to blood can sometimes be connected to the life-giving nature of blood, seen in such events as childbirth, as contrasted with the blood of injury or death.
==== United States market (brands, formats, and recent changes) ==== The leading seller in the e-cigarette market in the US is the Juul e-cigarette, which was introduced in June 2015. As of August 2018, Juul accounts for over 72% of the US e-cigarette market monitored by Nielsen, and its closest competitor—RJ Reynolds' Vuse—makes up less than 10% of the market. Juul rose to popularity quickly, growing by 700% in 2016 alone. On 17 July 2018 Reynolds announced it will debut in August 2018 a pod mod type device similar Juul. The popularity of the Juul pod system has led to a flood of other pod devices hitting the market. Since 2018 the US e-cigarette market has shifted. During January 2020-December 2022, disposable cigarette unit share increased from 24.7% to 51.8%, while prefilled cartridge share decreased from 75.2% to 48.0%. For the four-week period ending December 25, 2022, the top-selling brands were Vuse, JUUL, Elf Bar, NJOY, and Breeze Smoke. In the 52 weeks ended June 15, 2024, Vuse Alto products represented approximately 40% of U.S. e-cigarette sales in stores tracked by NielsenIQ, according to an analyst cited by The Wall Street Journal. In the US the Federal Trade Commission reported that e-cigarette product sales for major reporting manufacturers rose to $2.703 billion in 2019 and then declined to $2.224 billion in 2020, with the FTC noting this may reflect a shift to other market participants. In US retail scanner data, the number of e-cigarette brands increased from 184 in January 2020 to 269 in December 2022.
==== Chorion ==== The chorionic membrane is a fibrous tissue layer containing the fetal blood vessels. Chorionic villi form on the outer surface of the chorion, which maximise surface area for contact with maternal blood. The chorionic villi are involved in fetal-maternal exchange.
==== With Andy Burnham as Labour leader ==== In May 2026, amid Greater Manchester Mayor Andy Burnham's run in the 2026 Makerfield by-election and speculation of him challenging incumbent Labour leader and Prime Minister Keir Starmer, More in Common and Deltapoll conducted national polls with the condition of Burnham as leader. BMG Research then conducted a further poll after Starmer's resignation.
== Nearby points of interest == Gypsy Cove, known for its Magellanic penguins, and Cape Pembroke, the easternmost point of the Falklands, lie nearby. Gypsy Cove is four miles (6 km) from Stanley and can be reached by taxi or on foot.
Sources: en.wikipedia.org
Polyendocrine metabolic ovarian syndrome (PMOS) is an endocrine disorder characterized by an excess of androgens produced by the ovaries. It is estimated that approximately 90% of women with PMOS demonstrate hypersecretion of these hormones. The cause of this condition is unknown. Speculations include genetic predisposition; however, the gene or genes responsible for this remain unidentified. The condition may have a hereditary basis. Other possible causes include elevated insulin production. Most cases of PMOS involve insulin resistance. It is thought that adipose tissue dysfunction plays a role in the insulin resistance seen in PMOS. Insulin can induce excess testosterone secretion from the ovaries. A complication associated with polyendocrine metabolic ovarian syndrome is high cholesterol, which is treated with statins. In a meta-analysis, atorvastatin was shown to decrease androgen concentrations in people with hyperandrogenism. Elevated insulin leads to lower production of sex hormone binding globulin (SHBG), a regulatory glycoprotein that suppresses the function of androgens. High blood levels of insulin also work in conjunction with ovarian sensitivity to insulin to cause hyperandrogenemia, the primary symptom of PMOS. Obese individuals may be more biologically inclined to PMOS due to markedly higher insulin. This hormonal imbalance can lead to chronic anovulation, in which the ovaries fail to release mature eggs. These cases of ovulatory dysfunction are linked to infertility and menstrual disturbances.
The four substrates of this enzyme are 1-hydroxy-2-naphthoic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are 1,2-naphthalenediol, oxidised NAD+, water, and carbon dioxide. It is involved in chrysene degradation in some bacteria.
== Works == Simulated distillation of high-boiling petroleum fractions by capillary supercritical fluid chromatography and vacuum thermal gravimetric analysis, with Herbert E. Schwartz, Mieczyslaw M. Boduszynski, and Fu Su in Analytical Chemistry (journal), May 15, 1987
MVT-602 (other developmental code names RVT-602, TAK-448) is a kisspeptin receptor agonist which is under development for the treatment of female infertility and hypogonadism. It has been found to increase luteinizing hormone levels in premenopausal women. As of March 2021, MVT-602 is in phase 2 clinical trials for the treatment of female infertility and hypogonadism. It was also under development for the treatment of prostate cancer, but development for this indication was discontinued.
Sources: en.wikipedia.org
The practical role of protein structure prediction is now more important than ever. Massive amounts of protein sequence data are produced by modern large-scale DNA sequencing efforts such as the Human Genome Project. Despite community-wide efforts in structural genomics, the output of experimentally determined protein structures—typically by time-consuming and relatively expensive X-ray crystallography or NMR spectroscopy—is lagging far behind the output of protein sequences. The protein structure prediction remains an extremely difficult and unresolved undertaking. The two main problems are the calculation of protein free energy and finding the global minimum of this energy. A protein structure prediction method must explore the space of possible protein structures which is astronomically large. These problems can be partially bypassed in "comparative" or homology modeling and fold recognition methods, in which the search space is pruned by the assumption that the protein in question adopts a structure that is close to the experimentally determined structure of another homologous protein. In contrast, the de novo protein structure prediction methods must explicitly resolve these problems. The progress and challenges in protein structure prediction have been reviewed by Zhang.
This mixture of cells is then diluted and clones are grown from single parent cells on microtitre wells. The antibodies secreted by the different clones are then assayed for their ability to bind to the antigen (with a test such as ELISA or antigen microarray assay) or immuno-dot blot. The most productive and stable clone is then selected for future use. The hybridomas can be grown indefinitely in a suitable cell culture medium. They can also be injected into mice (in the peritoneal cavity, surrounding the gut). There, they produce tumors secreting an antibody-rich fluid called ascites fluid. The medium must be enriched during in vitro selection to further favour hybridoma growth. This can be achieved by the use of a layer of feeder fibrocyte cells or supplement medium such as briclone. Culture-media conditioned by macrophages can be used. Production in cell culture is usually preferred as the ascites technique is painful to the animal. Where alternate techniques exist, ascites is considered unethical.
== Background == In 1994, with record labels trying to capitalize on the popularity of grunge and alternative rock bands like Nirvana, Pearl Jam, and Soundgarden, Local H caught the attention of Polydor Records, which was then in the process of merging with Island Records. Island released the band's debut studio album, Ham Fisted, the following year, but it sold below expectations and Island pressured the band's A&R rep, Joe Bosso, to drop them. Instead, Bosso pushed them into quickly recording a follow-up before Island could cancel their contract. Ahead of the release of As Good as Dead, frontman Scott Lucas was informed by Island that the album needed to sell at least 100,000 copies for the band to remain with the label.
== Pathophysiological implications == In lean subjects it is significantly higher than in a population with obese persons. In several populations, SPINA-GR correlated with the area under the glucose curve and 2-hour concentrations of glucose, insulin and proinsulin in oral glucose tolerance testing, concentrations of free fatty acids, ghrelin and adiponectin, and the HbA1c fraction. SPINA-GR declines with increasing adherence to mediterranean diet, which may be explained by increased use of other macronutrients for energy production. In mice, SPINA-GR is reduced after they were fed a high-fat diet for one and three weeks. In hidradenitis suppurativa, an inflammatory skin disease, SPINA-GR is reduced. If this state is uncompensated by increased beta-cell function the static disposition index (SPINA-DI) is reduced, resulting in the onset of diabetes mellitus.
Changes in actin's folding occur in nemaline myopathy as well as changes in its aggregation and there are also changes in the expression of other associated proteins. In some variants where intranuclear bodies are found the changes in the folding masks the nucleus's protein exportation signal so that the accumulation of actin's mutated form occurs in the cell nucleus. On the other hand, it appears that mutations to ACTA1 that give rise to a CFTDM have a greater effect on sarcomeric function than on its structure. Recent investigations have tried to understand this apparent paradox, which suggests there is no clear correlation between the number of rods and muscular weakness. It appears that some mutations are able to induce a greater apoptosis rate in type II muscular fibres.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.